+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

China Precision Medicine Market: Focus on Ecosystems, Applications, and Competitive Landscape - Analysis and Forecast, 2019-2029

  • ID: 4808198
  • Report
  • Region: China
  • 236 Pages
  • BIS Research
1 of 6
China Precision Medicine Market to Reach $18,723.5 Million by 2029

FEATURED COMPANIES

  • Agena Biosciences, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • PerkinElmer, Inc.
  • WeGene
  • MORE

Key Questions Answered in this Report:

  • What are the major market drivers, challenges, and opportunities in the China precision medicine market?
  • What are the underlying structures resulting in the emerging trends within the China precision medicine market?
  • How will each segment of the China precision medicine market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2029?
  • What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2019-2029?
  • What are the key applications in China precision medicine market? What are the major segments of these applications?
  • What are the major technologies that are employed in the China precision medicine market? Which is the current dominant technology?
  • Who are the key manufacturers and service providers in the China precision medicine market, and what are their contributions? Moreover, what is the growth potential of each major precision medicine manufacturer and service provider?

The China Precision Medicine Industry Analysis projects the market to grow at a significant CAGR of 12.82% during the forecast period, 2019-2029. The China precision medicine market generated $4,919.7 million revenue in 2018, in terms of value.

The China Precision Medicine market growth is majorly driven by factors such as shifting the significance in medicine from reaction to prevention, government initiatives for the incorporation of precision medicine in China, lowering costs and advancement in sequencing technologies, and surge in underlying direct-to-consumer (DTC) genetic testing market in China. However, factors such as fragmented healthcare system in China, a lack of knowledge dissemination for advanced diagnostic capabilities, and a lack of a unified framework for big data integration hamper the overall market growth.

Expert Quote on the China Precision Medicine Market

“Announcement of the China Precision Medicine Initiative in 2016 has radically changed healthcare regimes in the country, with the renewed focus being directed toward capitalizing the present genome sequencing boom in the country. Further, with the establishment of the China Precision Medicine Cloud by WuXi NextCODE and Huawei, cloud-based genomics is anticipated to be the cornerstone of China’s precision medicine revolution.”

Scope of the Market Intelligence on China Precision Medicine Market

The China precision medicine market research provides a holistic view of the China precision medicine market in terms of various factors influencing it, including regulatory reforms, and technological advancements.

The scope of this report is centered upon conducting a detailed study of the products and services allied with the precision medicine market. In addition, the study also includes exhaustive information on the unmet needs, perception on the new products, competitive landscape, market share of leading manufacturers, the growth potential of each underlying sub-segment, and company, as well as other vital information with respect to China precision medicine market.

Market Segmentation

The China precision medicine market segmentation (on the basis of applied sciences) is further segmented into genomics, pharmacogenomics, and other applied sciences. Genomics is the prevalent applied sciences type in the China precision medicine market. This segment constitutes the majority shareholder in the applied sciences ecosystem for precision medicine and is also expected to continue dominating through 2029.

The China precision medicine market segmentation (on the basis of digital health and information technology) is segmented into CDSS, big data analytics, IT infrastructure, genome informatics, in-silicon informatics, and mobile health.

The China precision medicine market segmentation (on the basis of application) is segmented into oncology, infectious diseases, neurology/psychiatry, lifestyle and endocrinology, cardiology, gastroenterology, and other applications.

Key Companies in the China Precision Medicine Industry

The key manufacturers and service providers who have been contributing significantly to the china precision medicine market include Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., BGI Genomics Co., Ltd., Illumina, Inc., Shanghai Fosun Pharmaceutical Group, WuXi AppTec, Berry Genomics Co., Ltd., Agilent Technologies, Inc., and PerkinElmer Inc., among others.

Note: Product cover images may vary from those shown
2 of 6

FEATURED COMPANIES

  • Agena Biosciences, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • PerkinElmer, Inc.
  • WeGene
  • MORE

1 Market Overview
1.1 Precision Medicine: A Frontier in the Genesis of Patient-centric Medicine
1.2 Market Definition
1.3 The China Precision Medicine Initiative
1.4 Classification of China Precision Medicine Market
1.5 Market Footprint
1.6 Future Potential

2 Market Dynamics
2.1 Overview
2.2 Impact Analysis
2.3 Market Drivers
2.3.1 Shifting the Significance in Medicine from Reaction to Prevention
2.3.2 Government Initiatives for the Incorporation of Precision Medicine in China
2.3.3 Lowering Costs and Advancement in Sequencing Technologies
2.3.4 Surge in Underlying Direct-to-Consumer (DTC) Genetic Testing Market in China
2.4 Market Restraints
2.4.1 Fragmented Healthcare System in China
2.4.2 Lack of Knowledge Dissemination for Advanced Diagnostic Capabilities
2.4.3 Lack of a Unified Framework for Big Data Integration
2.5 Market Opportunities
2.5.1 Creation of a China-focused Population Database
2.5.2 Growing Demand for Health Security
2.5.3 Stakeholder-focused Strategies to Enable Global Partnerships and Overall Industry Growth in China

3 Competitive Landscape
3.1 Key Strategies and Developments
3.1.1 Synergistic Activities
3.1.2 Product Approvals
3.1.3 Business Expansion and Funding Activities
3.1.4 Product Launches and Enhancements
3.1.5 Acquisitions
3.2 Market Share Analysis, 2017 and 2018
3.3 Growth Share Analysis, 2018

4 Regulatory Framework
4.1 The National Medical Products Administration (NMPA)
4.2 Medical Device Regulations - NMPA
4.3 NMPA Medical Device Registration – The Current Scenario

5 China Precision Medicine Market (by Ecosystem), 2018-2029, ($Million)
5.1 Overview
5.2 Applied Sciences
5.2.1 China Precision Medicine Market (by Genomics)
5.2.1.1 China Precision Medicine Market (by Genomics, by Technology)
5.2.1.1.1 Polymerase Chain Reaction (PCR)
5.2.1.1.2 Next-Generation Sequencing (NGS)
5.2.1.1.3 Genome Editing
5.2.1.1.4 Other Technologies
5.2.2 China Precision Medicine Market (by Pharmacogenomics)
5.2.2.1 China Precision Medicine Market (by Pharmacogenomics, by Services)
5.2.2.2 China Precision Medicine Market (by Pharmacogenomics, by End Users)
5.2.3 China Precision Medicine Market (by Other Applied Sciences)
5.3 Precision Therapeutics
5.3.1 China Precision Medicine Market (by Clinical Trials)
5.3.2 China Precision Medicine Market (by Cell Therapy)
5.3.3 China Precision Medicine Market (by Drug Discovery and Research)
5.3.4 China Precision Medicine Market (by Gene Therapy)
5.4 Digital Health and Information Technology (DHIT)
5.4.1 China Precision Medicine Market (by CDSS)
5.4.2 China Precision Medicine Market (by Big Data Analytics)
5.4.3 China Precision Medicine Market (by IT Infrastructure)
5.4.4 China Precision Medicine Market (by Genome Informatics)
5.4.5 China Precision Medicine Market (by In-silico Informatics)
5.4.6 China Precision Medicine Market (by Mobile Health)
5.5 Precision Diagnostics
5.5.1 China Precision Medicine Market (by Molecular Diagnostics)
5.5.1.1 China Precision Medicine Market (by NIPT)
5.5.1.2 China Precision Medicine Market (by Companion Diagnostics)
5.5.1.3 China Precision Medicine Market (by Liquid Biopsy)
5.5.1.4 China Precision Medicine Market (by Other Molecular Diagnostics)
5.5.2 China Precision Medicine Market (by Medical Imaging)
5.5.2.1 China Precision Medicine Market (by Image Analytics)
5.5.2.2 China Precision Medicine Market (by Imaging CAD)

6 China Precision Medicine Market (by Application), 2018-2029, ($Million)
6.1 Overview
6.2 China Precision Medicine Market (by Oncology)
6.3 China Precision Medicine Market (by Infectious Diseases)
6.4 China Precision Medicine Market (by Neurology/Psychiatry)
6.5 China Precision Medicine Market (by Lifestyle and Endocrinology)
6.6 China Precision Medicine Market (by Cardiology)
6.7 China Precision Medicine Market (by Gastroenterology)
6.8 Other Applications

7 Company Profiles
7.1 Overview
7.2 Agena Biosciences, Inc.
7.2.1 Company Overview
7.2.2 Role of Agena Biosciences, Inc. in the China Precision Medicine Market
7.2.3 SWOT Analysis
7.3 Agilent Technologies, Inc.
7.3.1 Company Overview
7.3.2 Role of Agilent Technologies, Inc. in the China Precision Medicine Market
7.3.3 Financials
7.3.4 Key Insights about Financial Health of the Company
7.3.5 SWOT Analysis
7.4 Berry Genomics Co., Ltd.
7.4.1 Company Overview
7.4.2 Role of Berry Genomics Co., Ltd in the China Precision Medicine Market
7.4.3 Financials
7.4.4 SWOT Analysis
7.5 Beijing Genomics Institute (BGI) Genomics Co., Ltd
7.5.1 Company Overview
7.5.2 Role of Beijing Genomics Institute (BGI) Genomics Co., Ltd in the China Precision Medicine Market
7.5.3 Financials
7.5.4 Key Insights about Financial Health of the Company
7.5.5 SWOT Analysis
7.6 Danaher Corporation
7.6.1 Company Overview
7.6.2 Role of Danaher Corporation in the China Precision Medicine Market
7.6.3 Financials
7.6.4 Key Insights about Financial Health of the Company
7.6.5 SWOT Analysis
7.7 DiaCarta Inc.
7.7.1 Company Overview
7.7.2 Role of DiaCarta Inc. in the China Precision Medicine Market
7.7.3 SWOT Analysis
7.8 F. Hoffmann-La Roche Ltd
7.8.1 Company Overview
7.8.2 Role of F. Hoffmann-La Roche Ltd in the China Precision Medicine Market
7.8.3 Financials
7.8.4 Key Insights about Financial Health of the Company
7.8.5 SWOT Analysis
7.9 Illumina, Inc.
7.9.1 Company Overview
7.9.2 Role of Illumina, Inc. in the China Precision Medicine Market
7.9.3 Financials
7.9.4 Key Insights about Financial Health of the Company
7.9.5 SWOT Analysis
7.10   Novogene Corporation
7.10.1 Company Overview
7.10.2 Role of Novogene Corporation in the China Precision Medicine Market
7.10.3 SWOT Analysis
7.11   PerkinElmer, Inc.
7.11.1 Company Overview
7.11.2 Role of PerkinElmer, Inc. in the China Precision Medicine Market
7.11.3 Financials
7.11.4 SWOT Analysis
7.12   Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
7.12.1 Company Overview
7.12.2 Role of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. in the China Precision Medicine Market
7.12.3 Financials
7.12.4 SWOT Analysis
7.13   Shuwen Biotech Co. Ltd.
7.13.1 Company Overview
7.13.2 Role of Shuwen Biotech Co. Ltd. in the China Precision Medicine Market
7.13.3 SWOT Analysis
7.14   Thermo Fisher Scientific Inc.
7.14.1 Company Overview
7.14.2 Role of Thermo Fisher Scientific Inc. in the China Precision Medicine Market
7.14.3 Financials
7.14.4 Key Insights about Financial Health of the Company
7.14.5 SWOT Analysis
7.15   WuXi AppTec Co., Ltd.
7.15.1 Company Overview
7.15.2 Role of WuXi AppTec Co., Ltd. in the China Precision Medicine Market
7.15.3 Financials
7.15.4 Key Insights about Financial Health of the Company
7.15.5 SWOT Analysis
7.16   Xiamen Aide Biomedical Technology Co., Ltd.
7.16.1 Company Overview
7.16.2 Role of Xiamen Aide Biomedical Technology Co., Ltd. in the China Precision Medicine Market
7.16.3 Financials
7.16.4 Key Insights about Financial Health of the Company
7.16.5 SWOT Analysis
7.17   Chengdu 23Mofang Biotechnology Co., Ltd.
7.17.1 Company Overview
7.17.2 Role of Chengdu 23Mofang Biotechnology Co., Ltd. in the China Precision Medicine Market
7.18   iCarbonX Group Limited
7.18.1 Company Overview
7.18.2 Role of iCarbonX Group Limited in the China Precision Medicine Market
7.19   WeGene
7.19.1 Company Overview
7.19.2 Role of WeGene in the China Precision Medicine Market

8 Research Scope and Methodology
8.1 Research Scope
8.2 China Precision Medicine Market: Research Methodology
8.2.1 Primary Data Sources
8.2.2 Secondary Data Sources

List of Tables
Table 2.1: Impact Analysis of Market Drivers
Table 2.2: Impact Analysis of Market Restraints
Table 4.1: Registration Criteria for IVD Medical Devices as per the NMPA

List of Figures
Figure 1: Precision Medicine: A Multi-Faceted Approach to Patient Care
Figure 2: Impact of Market Drivers and Market Restraints on the China Precision Medicine Market
Figure 3: China Precision Medicine Market Snapshot
Figure 4: Dominating Segments of the China Precision Medicine Market, 2018 and 2029
Figure 5: China Precision Medicine Market (by Applied Sciences), 2018 and 2029
Figure 6: China Precision Medicine Market (by DHIT), 2018 and 2029
Figure 7: China Precision Medicine Market (by Application), 2018 and 2029
Figure 1.1: Precision Medicine: Remodeling the One-Size-Fits-All Theory to Individually Tailored Therapy
Figure 1.2: Classification of China Precision Medicine Market
Figure 1.3: China Precision Medicine Market, 2018-2029
Figure 2.1: Decreasing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
Figure 2.2: Population Representation in GWAS Studies (2016)
Figure 3.1: Share of Key Developments and Strategies, January 2016 – June 2019
Figure 3 2: Synergistic Activities Share (by Company), January 2016 – June 2019
Figure 3.3: Product Approvals Share (by Company), January 2016 – June 2019
Figure 3.4: Business Expansion and Funding Activities Share (by Company), January 2016 – June 2019
Figure 3.5: Market Share Analysis for the China Precision Medicine Market, 2017
Figure 3.6: Market Share Analysis for the China Precision Medicine Market, 2018
Figure 3.7: Growth Share Matrix for China Precision Medicine Market (by Companies), 2018
Figure 4.1: Medical Device Registration in China (2017)
Figure 4.2: Class III Medical Device Registration in China (2017)
Figure 5.1: China Precision Medicine Market (by Ecosystem)
Figure 5.2: China Precision Medicine Market (by Ecosystem), 2018 and 2029
Figure 5.3: China Precision Medicine Market (by Applied Sciences), 2018-2029
Figure 5.4: China Precision Medicine Market (by Applied Sciences Types), 2018 and 2029
Figure 5.5: China Precision Medicine Market (by Genomics), 2018-2029
Figure 5.6: China Precision Medicine Market (by Genomics, by Technology), 2018 and 2029
Figure 5.7: China Precision Medicine Market (by Genomics, by PCR), 2018-2029
Figure 5.8: China Precision Medicine Market (by Genomics, by PCR Product Types), 2018 and 2029
Figure 5.9: China Precision Medicine Market (by Genomics, by PCR End User), 2018 and 2029
Figure 5.10: China Precision Medicine Market (by Genomics, by NGS), 2018-2029
Figure 5.11: China Precision Medicine Market (by Genomics, by NGS Product Types), 2018 and 2029
Figure 5.12: China Precision Medicine Market (by Genomics, by NGS Technology), 2018 and 2029
Figure 5.13: China Precision Medicine Market (by Genomics, by NGS End User), 2018 and 2029
Figure 5.14: China Precision Medicine Market (by Genomics, by Genome Editing), 2018-2029
Figure 5.15: China Precision Medicine Market (by Genomics, by Genome Editing Product Types), 2018 and 2029
Figure 5.16: China Precision Medicine Market (by Genomics, by Genome Editing End Users), 2018 and 2029
Figure 5.17: China Precision Medicine Market (by Genomics, by Other Technologies), 2018-2029
Figure 5.18: China Precision Medicine Market (by Pharmacogenomics), 2018-2029
Figure 5.19: China Precision Medicine Market (by Pharmacogenomics Services), 2018-2029
Figure 5.20: China Precision Medicine Market (by Pharmacogenomics End Users), 2018-2029
Figure 5.21: China Precision Medicine Market (by Other Applied Sciences), 2018-2029
Figure 5.22: China Precision Medicine Market (by Precision Therapeutics), 2018-2029
Figure 5.23: China Precision Medicine Market (by Precision Therapeutics), 2018 and 2029
Figure 5.24: China Precision Medicine Market (by Clinical Trials), 2018-2029
Figure 5.25: China Precision Medicine Market (by Cell Therapy), 2018-2029
Figure 5.26: China Precision Medicine Market (by Drug Discovery and Research), 2018-2029
Figure 5.27: China Precision Medicine Market (by Gene Therapy), 2018-2029
Figure 5.28: China Precision Medicine Market (by DHIT), 2018-2029
Figure 5.29: China Precision Medicine Market (by DHIT), 2018 and 2029
Figure 5.30: China Precision Medicine Market (by DHIT End Users), 2018-2029
Figure 5.31: China Precision Medicine Market (by CDSS), 2018-2029
Figure 5.32: China Precision Medicine Market (by Big Data Analytics), 2018-2029
Figure 5.33: China Precision Medicine Market (by IT Infrastructure), 2018-2029
Figure 5.34: China Precision Medicine Market (by IT Infrastructure Types), 2018-2029
Figure 5.35: China Precision Medicine Market (by Genome Informatics), 2018-2029
Figure 5.36: China Precision Medicine Market (by Genome Informatics Product Types), 2018 and 2029
Figure 5.37: China Precision Medicine Market (by In-silico Informatics), 2018-2029
Figure 5.38: China Precision Medicine Market (by Mobile Health), 2018-2029
Figure 5.39: China Precision Medicine Market (by Precision Diagnostics), 2018-2029
Figure 5.40: China Precision Medicine Market (by Precision Diagnostics), 2018 and 2029
Figure 5.41: China Precision Medicine Market (by Molecular Diagnostics), 2018-2029
Figure 5.42: China Precision Medicine Market (by Molecular Diagnostic Types), 2018 and 2029
Figure 5.43: China Precision Medicine Market (by NIPT), 2018-2029
Figure 5.44: China Precision Medicine Market (by NIPT Platforms), 2018 and 2029
Figure 5.45: China Precision Medicine Market (by Companion Diagnostics), 2018-2029
Figure 5.46: China Precision Medicine Market (by Companion Diagnostics Technologies), 2018 and 2029
Figure 5.47: China Precision Medicine Market (by Companion Diagnostics Indications), 2018 and 2029
Figure 5.48: China Precision Medicine Market (by Liquid Biopsy), 2018-2029
Figure 5.49: China Precision Medicine Market (by Liquid Biopsy Indications), 2018 and 2029
Figure 5.50: China Precision Medicine Market (by Other Molecular Diagnostics), 2018-2029
Figure 5.51: China Precision Medicine Market (by Other Molecular Diagnostics), 2018 and 2029
Figure 5.52: China Precision Medicine Market (by Medical Imaging), 2018-2029
Figure 5.53: China Precision Medicine Market (by Medical Imaging Types), 2018 and 2029
Figure 5.54: China Precision Medicine Market (by Image Analytics), 2018-2029
Figure 5.55: China Precision Medicine Market (by Imaging CAD), 2018-2029
Figure 6.1: China Precision Medicine Market (by Application)
Figure 6.2: China Precision Medicine Market (by Application), 2018 and 2029
Figure 6.3: China Precision Medicine Market (by Oncology), 2018-2029
Figure 6.4: China Precision Medicine Market (by Infectious Diseases), 2018-2029
Figure 6.5: China Precision Medicine Market (by Neurology/Psychiatry), 2018-2029
Figure 6.6: China Precision Medicine Market (by Lifestyle and Endocrinology), 2018-2029
Figure 6.7: China Precision Medicine Market (by Cardiology), 2018-2029
Figure 6.8: China Precision Medicine Market (by Gastroenterology), 2018-2029
Figure 6.9: China Precision Medicine Market (by Other Applications), 2018-2029
Figure 7.1: Total Number of Companies Profiled
Figure 7.2: Agena Biosciences, Inc.: Overall Product Portfolio
Figure 7.3: Agena Biosciences, Inc.: SWOT Analysis
Figure 7.4: Agilent Technologies, Inc.: Overall Product Portfolio
Figure 7.5: Agilent Technologies, Inc.: Overall Financials, 2016-2018
Figure 7.6: Agilent Technologies, Inc.: Revenue (by Segment), 2016-2018
Figure 7.7: Agilent Technologies, Inc.: Revenue (by Region), 2016-2018
Figure 7.8: Agilent Technologies, Inc.: R&D Expenditure, 2016-2018
Figure 7.9: Agilent Technologies, Inc.: SWOT Analysis
Figure 7.10: Product Portfolio: Berry Genomics Co., Ltd
Figure 7.11: Berry Genomics Co., Ltd: Overall Financials, 2017-2018
Figure 7.12: Berry Genomics Co., Ltd: Revenue (by Segment), 2017-2018
Figure 7.13: Berry Genomics Co., Ltd: Revenue (by Region), 2017-2018
Figure 7.14: Berry Genomics Co., Ltd: SWOT Analysis
Figure 7.15: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Overall Product Portfolio
Figure 7.16: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Overall Financials, 2017-2018
Figure 7.17: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Revenue (by Segment), 2017-2018
Figure 7.18: Beijing Genomics Institute (BGI) Genomics Co., Ltd: Revenue (by Region), 2017-2018
Figure 7.19: Beijing Genomics Institute (BGI) Genomics Co., Ltd: R&D Expenditure, 2017-2018
Figure 7.20: Beijing Genomics Institute (BGI) Genomics Co., Ltd: SWOT Analysis
Figure 7.21: Danaher Corporation: Overall Product Portfolio
Figure 7.22: Danaher Corporation: Overall Financials, 2016-2018
Figure 7.23: Danaher Corporation: Revenue (by Business Segment), 2016-2018
Figure 7.24: Danaher Corporation: Revenue (by Region), 2016-2018
Figure 7.25: Danaher Corporation: R&D Expenditure, 2016-2018
Figure 7.26: Danaher Corporation: SWOT Analysis
Figure 7.27: DiaCarta Inc.: Overall Product Portfolio
Figure 7.28: DiaCarta Inc.: SWOT Analysis
Figure 7.29: F. Hoffmann-La Roche Ltd: Overall Product Portfolio
Figure 7.30: F. Hoffmann-La Roche Ltd: Overall Financials, 2016-2018
Figure 7.31: F. Hoffmann-La Roche Ltd: Revenue (by Segment), 2016-2018
Figure 7.32: F. Hoffmann-La Roche Ltd: Revenue Split for Diagnostics, 2016-2018
Figure 7.33: F. Hoffmann-La Roche Ltd: Revenue (by Region), 2016-2018
Figure 7.34: F. Hoffmann-La Roche Ltd: R&D Expenditure, 2016-2018
Figure 7.35: F. Hoffmann-La Roche Ltd: SWOT Analysis
Figure 7.36: Illumina, Inc.: Overall Product Portfolio
Figure 7.37: Illumina, Inc.: Overall Financials, 2016-2018
Figure 7.38: Illumina, Inc.: Revenue (by Segment), 2016-2018
Figure 7.39: Illumina, Inc.: Revenue (by Region), 2016-2018
Figure 7.40: Illumina, Inc.: R&D Expenditure, 2016-2018
Figure 7.41: Illumina, Inc.: SWOT Analysis
Figure 7.42: Novogene Corporation: Overall Product Portfolio
Figure 7.43: Novogene Corporation: SWOT Analysis
Figure 7.44: PerkinElmer, Inc.: Overall Product Portfolio
Figure 7.45: Perkin Elmer, Inc.: Overall Financials, (2016-2018)
Figure 7.46: Perkin Elmer, Inc.: Revenue (by Business Segment), 2016-2018
Figure 7.47: Perkin Elmer, Inc.: Revenue (by Region), 2016-2018
Figure 7.48: PerkinElmer, Inc.: R&D Expenditure, 2016-2018
Figure 7.49: PerkinElmer, Inc.: SWOT Analysis
Figure 7.50: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.: Overall Product Portfolio
Figure 7.51: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.: Overall Financials, 2016-2018
Figure 7.52: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.: Revenue (by Business Segment), 2016-2018
Figure 7.53: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.: Revenue (by Region), 2016-2018
Figure 7.54: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.: R&D Expenditure, 2016-2018
Figure 7.55: Shanghai Fosun Pharmaceutical (Group) Co., Ltd.: SWOT Analysis
Figure 7.56: Shuwen Biotech Co. Ltd.: Overall Product Portfolio
Figure 7.57: Shuwen Biotech Co. Ltd.: SWOT Analysis
Figure 7.58: Thermo Fisher Scientific Inc.: Overall Product Portfolio
Figure 7.59: Thermo Fisher Scientific Inc.: Overall Financials, 2016-2018
Figure 7.60: Thermo Fisher Scientific Inc.: Revenue (by Segment), 2016-2018
Figure 7.61: Thermo Fisher Scientific Inc.: Revenue (by Region), 2016-2018
Figure 7.62: Thermo Fisher Scientific Inc.: R&D Expenditure, 2016-2018
Figure 7.63: Thermo Fisher Scientific Inc.: SWOT Analysis
Figure 7.64: WuXi AppTec Co., Ltd.: Overall Product Portfolio
Figure 7.65: WuXi AppTec Co., Ltd.: Overall Financials, 2017-2018
Figure 7.66: WuXi AppTec Co., Ltd.: Revenue (by Segment), 2017-2018
Figure 7.67: WuXi AppTec Co., Ltd.: Revenue (by Region), 2017-2018
Figure 7.68: WuXi AppTec Co., Ltd.: R&D Expenditure, 2016-2018
Figure 7.69: WuXi AppTec Co., Ltd.: SWOT Analysis
Figure 7.70: Xiamen Aide Biomedical Technology Co., Ltd.: Overall Product Portfolio
Figure 7.71: Xiamen Aide Biomedical Technology Co., Ltd.: Overall Financials, 2016-2017
Figure 7.72: Xiamen Aide Biomedical Technology Co., Ltd.: Revenue (by Segment), 2016-2017
Figure 7.73: Xiamen Aide Biomedical Technology Co., Ltd.: Revenue (by Region), 2016-2017
Figure 7.74: Xiamen Aide Biomedical Technology Co., Ltd.: R&D Expenditure, 2016-2017
Figure 7.75: Xiamen Aide Biomedical Technology Co., Ltd.: SWOT Analysis
Figure 7.76: Chengdu 23Mofang Biotechnology Co., Ltd.: Overall Product Portfolio
Figure 7.77: iCarbonX Group Limited: Overall Product Portfolio
Figure 7.78: WeGene: Overall Product Portfolio
Figure 8.1: China Precision Medicine Market Segmentation
Figure 8.2: China Precision Medicine Market Research Methodology
Figure 8.3: Primary Research
Figure 8.4: Secondary Research
Figure 8.5: Data Triangulation
Figure 8.6: Bottom-up Approach (Segment-wise Analysis)
Figure 8.7: Top-down Approach (Segment-wise Analysis)
Figure 8.8: Assumptions and Limitations
Figure 8.9: Considered Factors for Data Prediction and Modeling

Note: Product cover images may vary from those shown
3 of 6

Loading
LOADING...

4 of 6

FEATURED COMPANIES

  • Agena Biosciences, Inc.
  • Danaher Corporation
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • PerkinElmer, Inc.
  • WeGene
  • MORE

According to the market intelligence report, titled “China Precision Medicine Market - Analysis and Forecast, 2019-2029”, the China precision medicine market was valued at $4,919.7 million in 2018 and is anticipated to grow over $18,723.5 million by 2029. The China precision medicine market is expected to grow at a double-digit compound annual growth rate in the forecast period 2019-2029, aided primarily by the impressive growth in the underlying ecosystems.

Precision medicine holds immense potential to restructure the healthcare industry. It enables the investigation of various diseases by evaluating the genetic makeup of an individual subject, thereby providing tailored therapeutic treatment to each patient. The multi-faceted approach to patient care involved in the precision medicine allows healthcare providers to avoid adverse drug reactions, improve methods of administration, focus efforts on prevention and earlier intervention, increase treatment options, and most importantly, improve the quality of life. With China becoming one of the fastest-growing countries to adopt and implement precision medicine on a large-scale basis, primarily due to a genome sequencing boom in the country, this study intends to understand and delve deep into the current scenario as well as the future prospects China holds in becoming a precision medicine juggernaut, globally.

Announcement of the China Precision Medicine Initiative in 2016 has radically changed healthcare regimes in the country, with the renewed focus being directed toward capitalizing the present genome sequencing boom in the country. Further, with the establishment of the China Precision Medicine Cloud by WuXi NextCODE and Huawei, cloud-based genomics is set to be the cornerstone of China’s precision medicine revolution.

Research Highlights:

  • The emergence of several advancements in the precision medicine industry, spear-headed by the insurgence of Direct-to-Consumer (DTC) genetic testing services, has revolutionized health regimes by largely targeting chronic diseases that need to be addressed immediately. With rapid developments taking place at an escalating pace, the industry is consistently evolving to provide more precise care.
  • In 2018, the applied sciences ecosystem was acknowledged as the major contributor to the China precision medicine market and is expected to grow at a CAGR of 10.64% during the forecast period 2019-2029.
  • In 2018, the digital health and information technology ecosystem was acknowledged as the fastest-growing ecosystem within the China precision medicine market, expected to grow at a CAGR of 14.09% during the forecast period 2019-2029.
  • Oncology is expected to witness a robust CAGR of 12.04% during the forecast period 2019-2029. However, the precision medicine market for cardiology is anticipated to witness the fastest growth of 15.61% during the forecast period 2019-2029.
  • Thermo Fisher Scientific Inc. is currently the largest shareholder in the China precision medicine market. This market dominance is attributed to the company’s presence within the market through its expansive product portfolio and due to significant marketing activities.

This market intelligence report provides a multi-dimensional view of the China precision medicine market in terms of market size and growth potential. This research report aims at answering various aspects of the China precision medicine market with the help of key factors driving the market, restraints that can possibly inhibit the overall growth of the market, and the current growth opportunities that are going to shape the future trajectory of the market expansion.

Furthermore, the competitive landscape chapter in the report explicates the competitive nature of the China market and enables the reader to get acquainted with the recent market activities, such as product launches & approvals, partnerships, collaborations, business expansions, as well as mergers and acquisitions, among others. The research report provides a comprehensive analysis of the product sales, manufacturers, service providers, and trend analysis by segments, and growth share analysis by China. Additionally, the report provides a comprehensive attractive analysis and opportunity analysis for the China precision medicine market.

This report is a meticulous compilation of research on more than 100 players in the market ecosystem and draws upon insights from in-depth interviews with the key opinion leaders of more than 15 leading companies, market participants, and vendors. The report also comprises 15 detailed company profiles including several key players, such as Thermo Fisher Scientific Inc., F. Hoffmann-La Roche Ltd., BGI Genomics Co., Ltd., Illumina, Inc., Shanghai Fosun Pharmaceutical Group, WuXi AppTec, Berry Genomics Co., Ltd., Agilent Technologies, Inc., and PerkinElmer Inc., among others. The report also consists of snapshot profiles of Chengdu 23Mofang Biotechnology Co., Ltd., iCarbonX Group Limited (iCarbonX), and WeGene which have been anticipated to be three of the fastest-growing companies with regard to the presence in the China precision medicine market.

The answers to the following key questions can be derived from this report:

  • What are the major market drivers, challenges, and opportunities in the China precision medicine market?
  • What are the underlying structures resulting in the emerging trends within the China precision medicine market?
  • How will each segment of the China precision medicine market grow during the forecast period and what will be the revenue generated by each of the segments by the end of 2029?
  • What are the key developmental strategies which are implemented by the major players in order to sustain in the competitive market? What are the key regulatory implications in China for precision medicine?
  • Who are the leading players with significant offerings to the China precision medicine market? What is the current market dominance for each of these leading players?
  • What would be the compound growth rate witnessed by the leading players in the market during the forecast period 2019-2029?
  • What are the key applications in China precision medicine market? What are the major segments of these applications?
  • What are the major technologies that are employed in the China precision medicine market? Which is the current dominant technology?
  • Who are the primary end-users of the China precision medicine market? Which is the fastest-growing end-use segment in the China precision medicine market?
  • Who are the key manufacturers and service providers in the China precision medicine market, and what are their contributions? Moreover, what is the growth potential of each major precision medicine manufacturer and service provider?
  • What is the scope of the China precision medicine market in China? What are the strategies being undertaken to sustain growth in the industry?

Key trends targeted in the report:

  • What are the emerging trends in the China precision medicine market? How are these trends revolutionizing the treatment procedure?
  • Which technologies are anticipated to break through the current precision medicine regime?
  • Which companies are anticipated to be highly disruptive in the future and why?
  • What are the regulatory procedures that are required to unify the approval process for emerging precision medicine products? How will these enhance the reimbursement scenario?
  • What are the gaps in regularizing optimum precision medicine adoption in regular healthcare routines? How are these gaps being tackled?
Note: Product cover images may vary from those shown
5 of 6
  • Agena Biosciences, Inc.
  • Agilent Technologies, Inc.
  • Berry Genomics Co., Ltd.
  • Beijing Genomics Institute (BGI) Genomics Co., Ltd
  • Danaher Corporation
  • DiaCarta Inc.
  • F. Hoffmann-La Roche Ltd
  • Illumina, Inc.
  • Novogene Corporation
  • PerkinElmer, Inc.
  • Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  • Shuwen Biotech Co. Ltd.
  • Thermo Fisher Scientific Inc.
  • WuXi AppTec Co., Ltd.
  • Xiamen Aide Biomedical Technology Co., Ltd.
  • Chengdu 23Mofang Biotechnology Co., Ltd.
  • iCarbonX Group Limited
  • WeGene
Note: Product cover images may vary from those shown
6 of 6

Loading
LOADING...

Adroll
adroll